Overview Evaluate Safety, Efficacy and Pharmacokinetics Status: Unknown status Trial end date: 2020-12-01 Target enrollment: Participant gender: Summary The purpose of the study is to demonstrate equivalent pharmacokinetics (PK) Phase: Phase 1/Phase 2 Details Lead Sponsor: CelltrionTreatments: Albumin-Bound PaclitaxelPaclitaxelTrastuzumab